Clinical Trial Update: Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study. [Phase 2]

View source ↗

Summary

Phase 2 pilot prospective study evaluating belatacept (Nulojix) in renal transplant recipients with mild immunologic risk factors, including acute antibody-medi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antibody-mediated Rejection
• Renal Transplant
• Renal Transplant Failure

Drugs mentioned

• belatacept (belatacept)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Renal Transplant, Acute Antibody Mediated Rejection | Phase 2 | Status: COMPLETED